Alport syndrome from bench to bedside: The potential of current treatment beyond RAAS blockade and the horizon of future therapies

Nephrology Dialysis Transplantation

Volumn 29, Issue , 2014, Pages iv124-iv130

  Gross, Oliver ^a   Perin, Laura ^b   Deltas, Constantinos ^c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Alport syndrome; Chaperon therapy; Discoidin domain receptor 1; Kidney fibrosis; MicroRNA 21

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CERIVASTATIN; COLLAGEN RECEPTOR; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISCOIDIN DOMAIN RECEPTOR 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA 21; PARICALCITOL; RENIN INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2; ANGIOTENSIN RECEPTOR ANTAGONIST;

ALPORT SYNDROME; CARDIOVASCULAR DISEASE; EMBRYONIC STEM CELL; GENOTYPE PHENOTYPE CORRELATION; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPARATHYROIDISM; INDUCED PLURIPOTENT STEM CELL; KIDNEY DEVELOPMENT; KIDNEY FIBROSIS; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RECURRENT INFECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STEM CELL TRANSPLANTATION; UNFOLDED PROTEIN RESPONSE; ADULT; CHAPERON THERAPY; DRUG EFFECT; GENETICS; MICRORNA-21; NEPHRITIS;

ALPORT SYNDROME; CHAPERON THERAPY; DISCOIDIN DOMAIN RECEPTOR 1; KIDNEY FIBROSIS; MICRORNA-21;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; COLLAGEN TYPE IV; HUMANS; NEPHRITIS, HEREDITARY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84910115740     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu028     Document Type: Review

References (50)

1. Hudson BG, Tryggvason K, Sundaramoorthy M et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348: 2543-2556
2. Boutaud A, Borza DB, Bondar O et al. Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 2000; 275: 30716-30724
3. Kalluri R, Shield CF, Todd P et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997; 99: 2470-2478
4. Abrahamson DR, Prettyman AC, Robert B et al. Laminin-1 reexpression in Alport mouse glomerular basement membranes. Kidney Int 2003; 63: 826-834
5. Kruegel J, Rubel D, Gross O. Alport syndrome - insights from basic and clinical research. Nat Rev Nephrol 2013; 9: 170-178
6. Lin X, Suh JH, Go G et al. Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol 2013; November 21. [Epub ahead of print]
7. Abrahamson DR, Hudson BG, Stroganova L et al. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 2009; 20: 1471-1479
8. Gross O, Netzer KO, Lambrecht R et al. Meta-analysis of genotypephenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002; 17: 1218-1227
9. Cosgrove D, Rodgers K, Meehan D et al. Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 2000; 157: 1649-1659
10. Gross O, Girgert R, Beirowski B et al. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 2010; 29: 346-356
11. Noone D, Licht C. An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol 2013; 28: 1025-1036
12. Ryu M, Migliorini A, Miosge N et al. Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury. J Pathol 2012; May 3. doi:10.1002/path.4046. [Epub ahead of print]
13. Gross O, Beirowski B, Koepke ML et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63: 438-446
14. Pohl M, Danz K, Gross O et al. Diagnosis of Alport syndrome - search for proteomic biomarkers in body fluids. Pediatr Nephrol 2013; 28: 2117-2123
15. Ryu M, Kulkarni OP, Radomska E et al. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. Kidney Int 2011; 79: 189-198
16. Rubel D, Stock J, Ciner A et al. Antifibrotic, nephroprotective effects of Paricalcitol versus Calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. Nephrol Dial Transplant 2014; 29: 1012-1019
17. Koepke ML, Weber M, Schulze-Lohoff E et al. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 2007; 22: 1062-1069
18. Kadler KE, Baldock C, Bella J et al. Collagens at a glance. J Cell Sci 2007; 120(Pt 12): 1955-1958
19. Constantinou CD, Nielsen KB, Prockop DJ. A lethal variant of osteogenesis imperfecta has a single base mutation that substitutes cysteine for glycine 904 of the alpha 1(I) chain of type I procollagen. The asymptomatic mother has an unidentified mutation producing an overmodified and unstable type I procollagen. J Clin Invest 1989; 83: 574-584
20. Vogel BE, Doelz R, Kadler KE et al. A substitution of cysteine for glycine 748 of the alpha 1 chain produces a kink at this site in the procollagen I molecule and an altered N-proteinase cleavage site over 225 nm away. J Biol Chem 1988; 263: 19249-19255
21. Hashimura Y, Nozu K, Kaito H et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV alpha5 chain. Kidney Int 2013; December 4. doi:10.1038/ki.2013.479. [Eepub ahead of print]
22. Powell K, Zeitlin PL. Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv Drug Deliv Rev 2002; 54: 1395-1408
23. Morello JP, Salahpour A, Laperriere A et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105: 887-895
24. Chen YM, Zhou Y, Go G et al. Laminin beta2 gene missense mutation produces endoplasmic reticulum stress in podocytes. J Am Soc Nephrol 2013; 24: 1223-1233
25. Ohashi T, Uchida K, Uchida S et al. Intracellular mislocalization of mutant podocin and correction by chemical chaperones. Histochem Cell Biol 2003; 119: 257-264
26. Murray LS, Lu Y, Taggart A et al. Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke. Hum Mol Genet 2014; 23: 283-292
27. Pieri M, Stefanou C, Zaravinos A et al. Evidence for activation of the unfolded protein response in collagen IV nephropathies. J Am Soc Nephrol 2014; 25: 260-275
28. Sugimoto H, Mundel TM, Sund M et al. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 2006; 103: 7321-7326
29. LeBleu V, Sugimoto H, Mundel TM et al. Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol 2009; 20: 2359-2370
30. Prodromidi EI, Poulsom R, Jeffery R et al. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 2006; 24: 2448-2455
31. Perin L, Da Sacco S, De Filippo RE. Regenerative medicine of the kidney. Adv Drug Deliv Rev 2011; 63: 379-387
32. Sedrakyan S, Da Sacco S, Milanesi A et al. Injection of amniotic fluid stem cells delays progression of renal fibrosis. J Am Soc Nephrol 2012; 23: 661-673
33. Wise AF, Ricardo SD. Mesenchymal stem cells in kidney inflammation and repair. Nephrology (Carlton) 2012; 17: 1-10
34. Williams TM, Little MH, Ricardo SD. Macrophages in renal development, injury, and repair. Semin Nephrol 2010; 30: 255-267
35. Kobayashi T, Tanaka H, Kuwana H et al. Wnt4-transformed mouse embryonic stem cells differentiate into renal tubular cells. Biochem Biophys Res Commun 2005; 336: 585-595
36. Kramer J, Steinhoff J, Klinger M et al. Cells differentiated from mouse embryonic stem cells via embryoid bodies express renal marker molecules. Differentiation 2006; 74: 91-104
37. Bruce SJ, Rea RW, Steptoe AL et al. In vitro differentiation of murine embryonic stem cells toward a renal lineage. Differentiation 2007; 75: 337-349
38. Hendry CE, Vanslambrouck JM, Ineson J et al. Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. J Am Soc Nephrol 2013; 24: 1424-1434
39. Mae S, Shono A, Shiota F et al. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun 2013; 4: 1367
40. Song B, Smink AM, Jones CV et al. The directed differentiation of human iPS cells into kidney podocytes. PLoS One 2012; 7: e46453
41. Takasato M, Maier B, Little MH. Recreating kidney progenitors from pluripotent cells. Pediatr Nephrol 2013; September 13. [Epub ahead of print]
42. Da Sacco S, Lemley KV, Sedrakyan S et al. A novel source of cultured podocytes. PLoS One 2013; 8: e81812
43. Drozdova T, Papillon J, Cybulsky AV. Nephrin missense mutations: induction of endoplasmic reticulum stress and cell surface rescue by reduction in chaperone interactions. Physiol Rep 2013; 1: e00086
44. Chau BN, Xin C, Hartner J et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012; 4: 121ra18
45. Dey N, Ghosh-Choudhury N, Kasinath BS et al. TGFβ-stimulated micro-RNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 2012; 7: e42316
46. Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927; 1: 504-506
47. Gross O, Licht C, Anders HJ et al. Early angiotensin converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81: 494-501
48. Temme J, Kramer A, Jager KJ et al. Outcomes of male patients with Alport syndrome on renal replacement therapy. Clin J Am Soc Nephrol 2012; 7: 1969-1976
49. Kashtan CE, Ding J, Gregory M et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013; 28: 5-11
50. Savige J, Gregory M, Gross O et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 2013; 24: 364-375